探索经常使用甲基苯丙胺的人的迷幻体验：一项国际调查的结果

IF 3.9 2区医学 Q1 PSYCHIATRY

Drug and alcohol dependence Pub Date : 2025-05-08 DOI:10.1016/j.drugalcdep.2025.112699

Dilara Bahceci , Krista Siefried , Maureen Steele , Mary Harrod , Georgina Bell , Monica J. Barratt , Christopher R. Nicholas , Anthony Rodgers , Peter S. Hendricks , Christopher S. Stauffer , Paul Liknaitzky , Jonathan Brett

{"title":"探索经常使用甲基苯丙胺的人的迷幻体验：一项国际调查的结果","authors":"Dilara Bahceci , Krista Siefried , Maureen Steele , Mary Harrod , Georgina Bell , Monica J. Barratt , Christopher R. Nicholas , Anthony Rodgers , Peter S. Hendricks , Christopher S. Stauffer , Paul Liknaitzky , Jonathan Brett","doi":"10.1016/j.drugalcdep.2025.112699","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Methamphetamine use disorder, associated with significant morbidity and mortality, has limited effective treatments. Psychedelic-assisted psychotherapy shows promise, but data on its safety and efficacy in this population are limited. This exploratory study describes the demographic, substance use, and mental health characteristics of people who used methamphetamine and psychedelics and the context and outcomes of their psychedelic experiences.</div></div><div><h3>Methods</h3><div>A retrospective survey collected data on demographics, substance use patterns, mental health, and psychedelic use. Binomial logistic regression explored associations of post-psychedelic positive mood and social functioning ('increased'/'not increased') and substance use ('reduced'/'not reduced') with demographics, psychosocial factors, mental health, substance use patterns, and psychedelic use context.</div></div><div><h3>Results</h3><div>Among 268 participants, 48.5 % had a diagnosed mental illness, 45.1 % were at risk of suicide, 61.2 % reported psychotic symptoms, 45.1 % had high-risk methamphetamine use, and 82.1 % had taken substances other than methamphetamine and psychedelics. Most psychedelic experiences were unplanned (52.6 %), recreationally motivated (73 %), and combined with other drugs (52.6 %). Post-experience, participants reported improved mood (59.3 %) and social functioning (49.6 %), and reduced use of methamphetamine (34.0 %) and other substances (35.1 %). Forward planning and less challenging experiences were linked to improved mood (aOR 1.84, <em>p</em> = 0.048; aOR 2.21, <em>p</em> = 0.012) and reduced substance use (aOR 2.27, <em>p</em> = 0.008; aOR 3.58, <em>p</em> < 0.001).</div></div><div><h3>Discussion</h3><div>Psychedelic use among people who use methamphetamine may improve mood and social function, and reduce substance use. The complex findings highlight the potential importance of psychosocial and environmental factors (“set and setting”) in determining outcomes, underscoring the need for controlled clinical trials and tailored harm reduction strategies.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"272 ","pages":"Article 112699"},"PeriodicalIF":3.9000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey\",\"authors\":\"Dilara Bahceci , Krista Siefried , Maureen Steele , Mary Harrod , Georgina Bell , Monica J. Barratt , Christopher R. Nicholas , Anthony Rodgers , Peter S. Hendricks , Christopher S. Stauffer , Paul Liknaitzky , Jonathan Brett\",\"doi\":\"10.1016/j.drugalcdep.2025.112699\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Methamphetamine use disorder, associated with significant morbidity and mortality, has limited effective treatments. Psychedelic-assisted psychotherapy shows promise, but data on its safety and efficacy in this population are limited. This exploratory study describes the demographic, substance use, and mental health characteristics of people who used methamphetamine and psychedelics and the context and outcomes of their psychedelic experiences.</div></div><div><h3>Methods</h3><div>A retrospective survey collected data on demographics, substance use patterns, mental health, and psychedelic use. Binomial logistic regression explored associations of post-psychedelic positive mood and social functioning ('increased'/'not increased') and substance use ('reduced'/'not reduced') with demographics, psychosocial factors, mental health, substance use patterns, and psychedelic use context.</div></div><div><h3>Results</h3><div>Among 268 participants, 48.5 % had a diagnosed mental illness, 45.1 % were at risk of suicide, 61.2 % reported psychotic symptoms, 45.1 % had high-risk methamphetamine use, and 82.1 % had taken substances other than methamphetamine and psychedelics. Most psychedelic experiences were unplanned (52.6 %), recreationally motivated (73 %), and combined with other drugs (52.6 %). Post-experience, participants reported improved mood (59.3 %) and social functioning (49.6 %), and reduced use of methamphetamine (34.0 %) and other substances (35.1 %). Forward planning and less challenging experiences were linked to improved mood (aOR 1.84, <em>p</em> = 0.048; aOR 2.21, <em>p</em> = 0.012) and reduced substance use (aOR 2.27, <em>p</em> = 0.008; aOR 3.58, <em>p</em> < 0.001).</div></div><div><h3>Discussion</h3><div>Psychedelic use among people who use methamphetamine may improve mood and social function, and reduce substance use. The complex findings highlight the potential importance of psychosocial and environmental factors (“set and setting”) in determining outcomes, underscoring the need for controlled clinical trials and tailored harm reduction strategies.</div></div>\",\"PeriodicalId\":11322,\"journal\":{\"name\":\"Drug and alcohol dependence\",\"volume\":\"272 \",\"pages\":\"Article 112699\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug and alcohol dependence\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0376871625001528\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol dependence","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0376871625001528","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

摘要

目的甲基苯丙胺使用障碍具有显著的发病率和死亡率，有效的治疗方法有限。迷幻辅助心理治疗显示出前景，但其在这一人群中的安全性和有效性数据有限。本探索性研究描述了使用甲基苯丙胺和致幻剂的人群的人口统计学、物质使用和心理健康特征，以及他们的致幻剂经历的背景和结果。方法回顾性调查收集人口统计学、药物使用模式、心理健康和致幻剂使用数据。二项逻辑回归探讨了迷幻后积极情绪和社会功能（“增加”/“未增加”）以及物质使用（“减少”/“未减少”）与人口统计学、社会心理因素、心理健康、物质使用模式和迷幻药使用背景的关联。结果在268名参与者中，48.5%被诊断患有精神疾病，45.1%有自杀风险，61.2%报告有精神病症状，45.1%有高危甲基苯丙胺使用，82.1%服用过甲基苯丙胺和致幻剂以外的物质。大多数迷幻体验是计划外的（52.6%），娱乐动机（73%），以及与其他药物联合使用（52.6%）。体验后，参与者报告情绪（59.3%）和社会功能（49.6%）得到改善，甲基苯丙胺（34.0%）和其他物质（35.1%）的使用减少。前瞻性计划和较少挑战的经历与改善情绪有关(aOR 1.84, p = 0.048；aOR 2.21, p = 0.012)和减少物质使用(aOR 2.27, p = 0.008；（or 3.58, p < 0.001）。使用甲基苯丙胺的人使用致幻剂可以改善情绪和社会功能，减少物质使用。这些复杂的发现突出了社会心理和环境因素（“设定和设定”）在决定结果方面的潜在重要性，强调了对照临床试验和量身定制的减少伤害战略的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey

Objective

Methamphetamine use disorder, associated with significant morbidity and mortality, has limited effective treatments. Psychedelic-assisted psychotherapy shows promise, but data on its safety and efficacy in this population are limited. This exploratory study describes the demographic, substance use, and mental health characteristics of people who used methamphetamine and psychedelics and the context and outcomes of their psychedelic experiences.

Methods

A retrospective survey collected data on demographics, substance use patterns, mental health, and psychedelic use. Binomial logistic regression explored associations of post-psychedelic positive mood and social functioning ('increased'/'not increased') and substance use ('reduced'/'not reduced') with demographics, psychosocial factors, mental health, substance use patterns, and psychedelic use context.

Results

Among 268 participants, 48.5 % had a diagnosed mental illness, 45.1 % were at risk of suicide, 61.2 % reported psychotic symptoms, 45.1 % had high-risk methamphetamine use, and 82.1 % had taken substances other than methamphetamine and psychedelics. Most psychedelic experiences were unplanned (52.6 %), recreationally motivated (73 %), and combined with other drugs (52.6 %). Post-experience, participants reported improved mood (59.3 %) and social functioning (49.6 %), and reduced use of methamphetamine (34.0 %) and other substances (35.1 %). Forward planning and less challenging experiences were linked to improved mood (aOR 1.84, p = 0.048; aOR 2.21, p = 0.012) and reduced substance use (aOR 2.27, p = 0.008; aOR 3.58, p < 0.001).

Discussion

Psychedelic use among people who use methamphetamine may improve mood and social function, and reduce substance use. The complex findings highlight the potential importance of psychosocial and environmental factors (“set and setting”) in determining outcomes, underscoring the need for controlled clinical trials and tailored harm reduction strategies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug and alcohol dependence 医学-精神病学

CiteScore

7.40

自引率

7.10%

发文量

409

审稿时长

41 days

期刊介绍： Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro and in vivo investigations of their biochemical, pharmacological and behavioural actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, and studies employing methods from epidemiology, sociology, and economics.